Compare Flux Power Holdings Inc (FLUX) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Flux Power Holdings Inc trades at $0.43 (market cap $10.06M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 485.1× Flux Power Holdings Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 21 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FLUX | TVTX | |
|---|---|---|
Market Cap | $10.06M | $4.88B |
Volume | 188,430 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $6.66 | $67.52 |
52-Week Low | $0.41 | $26.79 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $18.26M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.4652, down 0.04% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported revenue of $66.43 million in 2025 but posted a net loss of $6.67 million, with profitability metrics showing negative ROE and ROA. Recent news highlights acquisition interest from Solidion Technology, which Flux Power's board rejected in October 2026, creating uncertainty around strategic direction.
The outlook remains challenged by persistent losses and declining revenue projections for 2026, though analyst consensus is unanimously bullish with 6 buy ratings. Key risks include execution on profitability, competitive pressures in energy storage, and potential acquisition volatility. The stock's valuation at 0.22 P/S offers potential if operational improvements materialize.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
